enGene (NASDAQ:ENGN) Receives Market Perform Rating from Citizens Jmp

enGene (NASDAQ:ENGN)‘s stock had its “market perform” rating reaffirmed by equities research analysts at Citizens Jmp in a research note issued to investors on Wednesday, Benzinga reports.

A number of other research firms have also commented on ENGN. UBS Group lowered their price target on enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Wall Street Zen upgraded enGene from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Citigroup reissued a “market perform” rating on shares of enGene in a research note on Wednesday. Weiss Ratings restated a “sell (e+)” rating on shares of enGene in a report on Wednesday, August 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of enGene in a research note on Tuesday. Four research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $11.05.

enGene Trading Up 5.5%

NASDAQ:ENGN opened at $1.92 on Wednesday. The company has a fifty day moving average of $1.82 and a 200 day moving average of $4.05. enGene has a 52 week low of $1.40 and a 52 week high of $12.25. The company has a quick ratio of 12.57, a current ratio of 12.57 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $128.62 million, a P/E ratio of -0.88 and a beta of -0.28.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). On average, research analysts predict that enGene will post -1.75 earnings per share for the current year.

Hedge Funds Weigh In On enGene

A number of hedge funds have recently bought and sold shares of ENGN. Cresset Asset Management LLC bought a new stake in enGene during the 2nd quarter valued at about $36,000. Raymond James Financial Inc. raised its holdings in enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares during the last quarter. Paloma Partners Management Co purchased a new position in enGene in the 2nd quarter worth approximately $38,000. Jump Financial LLC bought a new position in enGene in the 4th quarter valued at approximately $121,000. Finally, Millennium Management LLC lifted its position in enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after acquiring an additional 7,472 shares in the last quarter. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.